Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations

Fig. 3

Effect of anti-cytokine treatment on inflammation markers (step 3). Patients with psoriatic arthritis received treatment with either tumor necrosis factor inhibitor adalimumab (TNFi; N = 10) or interleukin-17 inhibitor secukinumab (IL-17i; N = 10). Serum was analyzed for beta-defensin 2 (BD2), lipocalin 2 (LC2), interleukin (IL)-22, interleukin (IL)-8, and calprotectin (CAL) at baseline and 3 months follow-up

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us